Mark Wickens

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

M. William Audeh, James Carmichael, Richard T. Penson et al. · The Lancet · 2010 · 2.3K citations

Medicine, Cancer Management, Gynecology +7

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

Andrew Tutt, Mark E. Robson, Judy E. Garber et al. · The Lancet · 2010 · 1.6K citations

Breast Oncology, Oncology, Pathology +6

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin

Steen Husted, Håkan Emanuelsson, Stan Heptinstall et al. · European Heart Journal · 2006 · 738 citations · Full text

Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes

Robert F. Storey, Steen Husted, Robert A. Harrington et al. · Journal of the American College of Cardiology · 2007 · 484 citations

Thrombopoiesis, Thrombosis, Platelet Aggregation Inhibitors +12

Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With <i>BRCA1</i> or <i>BRCA2</i> Mutations and Recurrent Ovarian Cancer

Stan B. Kaye, Jan Lubiński, Ursula A. Matulonis et al. · Journal of Clinical Oncology · 2011 · 472 citations